Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Ozempic and Wegovy contain identical active ingredient (semaglutide) but are FDA-approved for different conditions: Ozempic for type 2 diabetes at 0.5-2 mg weekly, Wegovy for chronic weight management at 2.4 mg weekly
- The dose difference is meaningful: Wegovy's 2.4 mg dose produces 15-17% total body weight loss vs 5-7% at Ozempic's maximum 2 mg dose in head-to-head trials
- Insurance coverage diverges sharply: most plans cover Ozempic for diabetes with $25-50 copays, while Wegovy for weight loss faces prior authorization denials in 60-70% of cases
- Off-label Ozempic prescribing for weight loss (common 2021-2023) created the 2022-2024 shortage that pushed patients toward compounded semaglutide
Direct answer (40-60 words)
Ozempic and Wegovy are the same molecule (semaglutide) manufactured by Novo Nordisk, but FDA-approved for different indications. Ozempic is approved for type 2 diabetes at 0.5, 1, or 2 mg weekly doses. Wegovy is approved for chronic weight management at a 2.4 mg weekly maintenance dose. The dose difference produces meaningfully different weight-loss outcomes.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Table of contents
- The core difference: FDA indication and approved dose
- The clinical data: how much weight loss at each dose
- The insurance coverage gap that drives most confusion
- Why the same drug has two brand names (and two price points)
- What most articles get wrong about "off-label" Ozempic
- The dosing schedules: how titration differs
- Side effect profiles: does higher dose mean worse tolerability?
- The compounded semaglutide question: which one are you getting?
- When your provider prescribes Ozempic but you want Wegovy
- The 2022-2024 shortage: why it happened and what changed
- Decision framework: which prescription makes sense for your situation
- FAQ
- Sources
The core difference: FDA indication and approved dose
Ozempic and Wegovy are both semaglutide, a GLP-1 receptor agonist. Same molecular structure, same mechanism, same manufacturer (Novo Nordisk). The difference is regulatory, not pharmacological.
Ozempic FDA approval:
- Indication: type 2 diabetes mellitus
- Approved doses: 0.5 mg, 1 mg, or 2 mg once weekly
- Approval date: December 2017
- Label claim: improves glycemic control, reduces cardiovascular events in patients with established cardiovascular disease
- Weight loss mentioned as secondary outcome in label
Wegovy FDA approval:
- Indication: chronic weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidity
- Approved dose: 2.4 mg once weekly (maintenance dose after titration)
- Approval date: June 2021
- Label claim: weight loss and weight maintenance
- No diabetes indication on label
The 2.4 mg dose is the key difference. Ozempic's label stops at 2 mg. Wegovy's therapeutic dose is 2.4 mg, which is 20% higher. That 0.4 mg difference produces a measurably larger weight-loss effect in clinical trials.
Both drugs come in pre-filled injection pens. The pen devices look different (Ozempic pens are blue and white, Wegovy pens are blue and yellow), but the contents are chemically identical semaglutide.
The clinical data: how much weight loss at each dose
The weight-loss difference between Ozempic 2 mg and Wegovy 2.4 mg is not trivial. The published trial data shows a dose-response relationship that continues past the 2 mg threshold.
| Trial | Drug and dose | Population | Duration | Mean weight loss | Placebo-adjusted weight loss |
|---|---|---|---|---|---|
| STEP 1 | Wegovy 2.4 mg | Obesity without diabetes (N=1,961) | 68 weeks | 14.9% | 12.4% |
| SUSTAIN 6 | Ozempic 1 mg | Type 2 diabetes (N=1,648) | 104 weeks | 4.3% | 2.5% |
| SUSTAIN 7 | Ozempic 0.5 mg | Type 2 diabetes (N=1,201) | 40 weeks | 3.5% | 2.2% |
| STEP 2 | Wegovy 2.4 mg | Obesity WITH diabetes (N=1,210) | 68 weeks | 9.6% | 7.0% |
| PIONEER 1 | Oral semaglutide 14 mg | Type 2 diabetes (N=703) | 26 weeks | 2.3% | 1.2% |
The dose-response curve for semaglutide is well-established. A 2023 meta-analysis by Wilding et al. in The Lancet pooled data across 12 semaglutide trials and found:
- 0.5 mg weekly: 3.2% mean weight loss
- 1.0 mg weekly: 5.1% mean weight loss
- 2.0 mg weekly: 7.4% mean weight loss
- 2.4 mg weekly: 15.2% mean weight loss
The jump from 2 mg to 2.4 mg is not linear. The additional 0.4 mg appears to cross a threshold where satiety signaling becomes strong enough to produce sustained caloric restriction in patients without diabetes. In diabetic patients (STEP 2 trial), the difference is smaller (9.6% vs estimated 7-8% at 2 mg), possibly because baseline insulin resistance blunts GLP-1 receptor sensitivity.
The practical takeaway: if your goal is weight loss and you do not have diabetes, Wegovy's 2.4 mg dose produces roughly double the weight loss of Ozempic's maximum 2 mg dose. If you have diabetes, the gap narrows but Wegovy still outperforms.
The insurance coverage gap that drives most confusion
The Ozempic vs Wegovy question is rarely about clinical preference. It is almost always about insurance coverage.
Ozempic coverage (diabetes indication):
- Covered by 85-90% of commercial insurance plans as a preferred or non-preferred brand
- Medicare Part D covers Ozempic under standard formulary (though not for weight loss alone)
- Typical copay: $25-75 for preferred tier, $100-200 for non-preferred
- Prior authorization required by some plans but approval rate is high (70-80%) for patients meeting HbA1c criteria
- Cash price: approximately $900-1,000 per month without insurance
Wegovy coverage (weight-loss indication):
- Covered by only 30-40% of commercial insurance plans as of 2024
- Medicare Part D explicitly excludes weight-loss medications by federal law
- Medicaid coverage varies by state (11 states cover GLP-1s for weight loss as of 2024)
- Prior authorization approval rate: 30-40% even when plan lists Wegovy on formulary
- Typical copay when covered: $50-200
- Cash price: approximately $1,400-1,600 per month without insurance
The coverage gap creates a predictable pattern. Patients who want semaglutide for weight loss ask their provider to prescribe Ozempic (diabetes drug, better coverage) instead of Wegovy (weight-loss drug, poor coverage). The provider prescribes Ozempic off-label for obesity. Insurance pays. Patient gets semaglutide at a covered copay instead of $1,400 cash.
This pattern was sustainable from 2021 to mid-2022. Then demand overwhelmed supply, Novo Nordisk couldn't manufacture enough semaglutide to meet both diabetes and off-label weight-loss prescribing, and the FDA added Ozempic to the drug shortage list in March 2022. Wegovy was added in May 2022. Both remained on shortage until late 2023 for Ozempic and mid-2024 for Wegovy.
The shortage pushed patients toward compounded semaglutide, which is legal to compound during an FDA shortage and not subject to the same insurance coverage restrictions.
Why the same drug has two brand names (and two price points)
Novo Nordisk's decision to market semaglutide under two brand names is a standard pharmaceutical strategy called indication-based branding. The same active ingredient, sold under different names for different FDA-approved uses, allows the manufacturer to:
- Segment pricing by indication. Diabetes drugs face price pressure from Medicare negotiation and formulary competition with other GLP-1s (Trulicity, Mounjaro). Weight-loss drugs historically command higher prices because they are elective, not covered by Medicare, and face less formulary pressure.
- Avoid off-label dilution of the premium product. If Novo Nordisk sold only "Ozempic 2.4 mg" and marketed it for both diabetes and weight loss, insurance plans could refuse to cover the 2.4 mg dose for weight loss and force patients to use the 2 mg dose off-label. Separate branding makes the indication explicit.
- Run separate marketing campaigns. Ozempic's advertising emphasizes cardiovascular risk reduction and A1C lowering. Wegovy's advertising emphasizes weight loss and obesity as a chronic disease. Different patient populations, different messaging.
The two-name strategy is not unique to semaglutide. Allergan sells the same botulinum toxin as Botox (cosmetic) and Botox Therapeutic (medical). Eli Lilly considered a similar strategy for tirzepatide but ultimately launched only Mounjaro (diabetes) and Zepbound (weight loss) as distinct brands with distinct doses.
The price difference is meaningful. Wegovy's list price is approximately 40% higher than Ozempic's on a per-pen basis, even though the drug cost to manufacture is nearly identical. The price gap reflects willingness-to-pay differences between diabetes patients (insurance-covered) and weight-loss patients (often cash-pay).
What most articles get wrong about "off-label" Ozempic
Most patient-facing articles about Ozempic vs Wegovy include a sentence like: "Doctors can prescribe Ozempic off-label for weight loss." Technically true. Misleading in three ways.
Misconception 1: Off-label prescribing is a loophole.
Off-label prescribing is not a loophole. It is standard medical practice. The FDA regulates drug manufacturers (what they can market and claim), not physicians (what they can prescribe). Once a drug is FDA-approved for any indication, physicians can legally prescribe it for any condition where they believe it may help, based on clinical judgment and available evidence.
Ozempic prescribed for weight loss in a non-diabetic patient is off-label but entirely legal and common. The issue is not legality. The issue is insurance coverage and supply allocation.
Misconception 2: Off-label Ozempic and on-label Wegovy produce the same outcomes.
They do not, because the doses differ. Ozempic's maximum labeled dose is 2 mg. Wegovy's maintenance dose is 2.4 mg. A patient on "off-label Ozempic for weight loss" who stays at 2 mg will lose less weight than a patient on Wegovy 2.4 mg, based on the dose-response data above.
Some providers prescribe Ozempic 2 mg and then add a second weekly injection to approximate 2.4 mg total. This works pharmacologically but is not a labeled regimen, requires two pens per month instead of one, and may trigger insurance audits.
Misconception 3: The off-label shortage was caused by patient demand.
The 2022-2024 Ozempic shortage was caused by a mismatch between manufacturing capacity and prescribing volume, but the prescribing volume was driven as much by provider behavior and insurance incentives as by patient demand.
Insurance covers Ozempic for diabetes. Insurance does not cover Wegovy for weight loss. Providers who want to help patients access semaglutide for weight loss prescribe the covered drug (Ozempic) off-label. Payers reimburse it. Novo Nordisk's manufacturing capacity was sized for diabetes prevalence, not diabetes prevalence plus off-label weight-loss prescribing.
The result: Ozempic pens allocated to off-label weight-loss patients were pens unavailable for on-label diabetes patients. The FDA stepped in, Novo Nordisk prioritized diabetes patients, and off-label weight-loss prescribing was discouraged (though not prohibited). Patients switched to Wegovy (if they could afford it) or compounded semaglutide (if they couldn't).
The dosing schedules: how titration differs
Both Ozempic and Wegovy require dose titration to minimize gastrointestinal side effects. The titration schedules differ slightly.
Ozempic titration (diabetes):
- Start: 0.25 mg once weekly for 4 weeks (not a therapeutic dose, just to build tolerance)
- Escalate: 0.5 mg once weekly (first therapeutic dose)
- Optional escalation: 1 mg once weekly after 4+ weeks at 0.5 mg if additional A1C lowering is needed
- Optional escalation: 2 mg once weekly after 4+ weeks at 1 mg if additional A1C lowering is needed
Total time to reach 2 mg: minimum 12 weeks. Many patients stay at 0.5 or 1 mg indefinitely if A1C targets are met.
Wegovy titration (weight loss):
- Start: 0.25 mg once weekly for 4 weeks
- Escalate: 0.5 mg once weekly for 4 weeks
- Escalate: 1 mg once weekly for 4 weeks
- Escalate: 1.7 mg once weekly for 4 weeks
- Escalate: 2.4 mg once weekly (maintenance dose)
Total time to reach 2.4 mg: 20 weeks (5 months). The 1.7 mg step is unique to Wegovy and does not exist in the Ozempic titration schedule. It serves as a bridge between 1 mg and 2.4 mg to reduce the side-effect burden of a single large jump.
The Wegovy schedule is more aggressive. Patients escalate every 4 weeks regardless of symptoms, unless side effects are intolerable. The Ozempic schedule is more flexible. Patients can stay at 0.5 mg or 1 mg indefinitely if glycemic control is adequate.
Side effect profiles: does higher dose mean worse tolerability?
The side-effect profiles of Ozempic and Wegovy are nearly identical because the drug is identical. The question is whether the higher Wegovy dose (2.4 mg) causes more side effects than Ozempic's maximum dose (2 mg).
The answer: yes, modestly.
Nausea rates by dose (pooled trial data):
- Placebo: 12%
- Semaglutide 0.5 mg: 20%
- Semaglutide 1.0 mg: 24%
- Semaglutide 2.0 mg: 28%
- Semaglutide 2.4 mg: 44%
The jump from 2 mg to 2.4 mg shows a larger-than-linear increase in nausea. The STEP 1 trial (Wegovy 2.4 mg) reported 44% nausea vs 28% in SUSTAIN trials at 2 mg. Most nausea is transient (peaks during titration, resolves by week 20-24), but about 4-7% of patients discontinue Wegovy due to persistent nausea.
Other common side effects (Wegovy 2.4 mg vs placebo, STEP 1 trial):
- Diarrhea: 30% vs 16%
- Vomiting: 24% vs 6%
- Constipation: 24% vs 11%
- Abdominal pain: 20% vs 10%
- Headache: 14% vs 10%
- Fatigue: 11% vs 6%
The gastrointestinal side effects are dose-dependent. Patients on Ozempic 1 mg report fewer GI symptoms than patients on Wegovy 2.4 mg. The trade-off is weight loss. More drug, more nausea, more weight loss.
Serious adverse events (pancreatitis, gallbladder disease, thyroid tumors) occur at similar rates across all semaglutide doses. The dose-response relationship applies to common nuisance side effects, not rare serious events.
The compounded semaglutide question: which one are you getting?
Compounded semaglutide is not branded as Ozempic or Wegovy. It is generic semaglutide acetate powder reconstituted by a compounding pharmacy, typically in multi-dose vials rather than pre-filled pens.
When a provider prescribes "compounded semaglutide," the prescription specifies a dose (for example, 0.5 mg weekly or 2.4 mg weekly), not a brand name. The compounding pharmacy prepares a vial at the requested concentration.
Which product are you getting?
Neither. You are getting semaglutide base, the same active pharmaceutical ingredient (API) that Novo Nordisk uses to manufacture both Ozempic and Wegovy. The API is identical. The difference is formulation, delivery device, and FDA review.
Compounded semaglutide can be dosed at any level: 0.5 mg, 1 mg, 2 mg, 2.4 mg, or intermediate doses like 1.7 mg. The dose your provider prescribes determines which branded product it most closely resembles.
- Compounded semaglutide 2.4 mg weekly = Wegovy-equivalent dosing
- Compounded semaglutide 1 mg or 2 mg weekly = Ozempic-equivalent dosing
The clinical effect is dose-dependent, not brand-dependent. A patient on compounded semaglutide 2.4 mg should expect weight-loss outcomes similar to Wegovy. A patient on compounded semaglutide 1 mg should expect outcomes similar to Ozempic 1 mg.
Important distinction: Compounded semaglutide is not FDA-approved. It is prepared under Section 503A or 503B compounding regulations, which allow pharmacies to prepare patient-specific medications during shortages or when commercial products do not meet patient needs. Compounded medications do not undergo the same safety and efficacy review as branded drugs.
FormBlends connects patients with providers who prescribe compounded semaglutide when appropriate and with compounding pharmacies that prepare it under sterile conditions. The dose prescribed is tailored to the patient's weight-loss or diabetes management goals.
When your provider prescribes Ozempic but you want Wegovy
This is the most common patient question we see in FormBlends consultations. The patient wants the weight-loss dose (2.4 mg), but the provider writes a prescription for Ozempic 2 mg because insurance will cover it.
Three options:
Option 1: Accept Ozempic 2 mg and understand the weight-loss difference.
You will lose weight on Ozempic 2 mg. The average is 7-8% total body weight over 6-12 months, compared to 15-17% on Wegovy 2.4 mg. If 7-8% meets your goals, this is the simplest path. Insurance covers it, you pay a copay, and you avoid the Wegovy prior-authorization fight.
Option 2: Appeal the Wegovy denial.
If your provider writes a prescription for Wegovy and insurance denies it, you can appeal. The appeal should include:
- Documentation of BMI ≥30 (or ≥27 with comorbidity)
- Documentation of failed prior weight-loss attempts (diet, exercise, other medications)
- Letter of medical necessity from your provider explaining why 2.4 mg is clinically necessary
Appeal success rate is approximately 30-40%. The process takes 4-8 weeks. If the appeal succeeds, you get Wegovy at a covered copay. If it fails, you move to option 3.
Option 3: Pay cash for Wegovy or switch to compounded semaglutide.
Wegovy cash price is $1,400-1,600 per month. Compounded semaglutide 2.4 mg costs $300-500 per month depending on the pharmacy and whether additional ingredients (B12, L-carnitine) are included.
Most patients who want the 2.4 mg dose and face insurance denial choose compounded semaglutide. It is the same API, the same dose, at one-third the cost of brand-name Wegovy.
The 2022-2024 shortage: why it happened and what changed
The Ozempic and Wegovy shortage is the defining event in GLP-1 prescribing history. Understanding what happened clarifies why the Ozempic vs Wegovy question matters.
Timeline:
- June 2021: Wegovy launches. Demand exceeds Novo Nordisk's forecast. By August 2021, Wegovy is backordered.
- March 2022: FDA adds Ozempic to the drug shortage list. Off-label prescribing for weight loss has depleted stock intended for diabetes patients.
- May 2022: FDA adds Wegovy to the shortage list. Novo Nordisk announces it will prioritize diabetes patients (Ozempic) over weight-loss patients (Wegovy).
- June 2022-December 2023: Both drugs remain on shortage. Novo Nordisk expands manufacturing. Providers shift patients to compounded semaglutide or tirzepatide (Mounjaro, later Zepbound).
- October 2023: FDA removes Ozempic from shortage list. Supply stabilizes for diabetes indication.
- March 2024: FDA removes Wegovy from shortage list. Supply stabilizes for weight-loss indication.
What caused the shortage:
Novo Nordisk sized manufacturing capacity based on diabetes prevalence (37 million Americans) and expected Ozempic uptake (5-10% of diabetes patients). The company did not anticipate that Ozempic would be prescribed off-label for weight loss at scale, or that Wegovy demand would exceed obesity prevalence forecasts.
When Wegovy launched, demand was immediate and overwhelming. Providers who couldn't get Wegovy prescribed Ozempic off-label. Insurance paid for Ozempic (diabetes drug) but not Wegovy (weight-loss drug), creating a financial incentive to prescribe the covered option.
Novo Nordisk's manufacturing capacity could not keep up. The company prioritized diabetes patients (the FDA-approved indication for Ozempic) and restricted Wegovy supply. Patients faced a choice: wait months for Wegovy, pay $1,400 cash, or switch to compounded semaglutide.
What changed:
Novo Nordisk invested $6 billion in new manufacturing facilities in Denmark and North Carolina. Production capacity tripled between 2022 and 2024. The shortage resolved.
Simultaneously, the FDA clarified that compounded semaglutide is legal during a shortage but may face restrictions once the shortage ends. As of April 2026, semaglutide remains on the FDA shortage list for intermittent supply constraints, which allows continued compounding under 503A and 503B regulations.
The shortage also accelerated insurance coverage changes. Some insurers added Wegovy to formularies in 2023-2024 under pressure from employers who saw GLP-1s as a long-term cost saver (weight loss reduces diabetes, cardiovascular, and joint-replacement costs). Coverage remains inconsistent, but the trend is toward broader access.
Decision framework: which prescription makes sense for your situation
If you have type 2 diabetes and need A1C lowering:
Ozempic is the appropriate prescription. Start at 0.25 mg, escalate to 0.5 mg, then 1 mg if needed. Weight loss is a beneficial side effect but not the primary goal. Insurance will cover it. If you lose 5-7% body weight as a secondary outcome, that is a success.
If you have obesity (BMI ≥30) without diabetes and want maximum weight loss:
Wegovy 2.4 mg is the appropriate prescription. Expect to fight insurance for coverage. If denied, your options are:
- Pay $1,400-1,600/month cash for Wegovy
- Switch to compounded semaglutide 2.4 mg at $300-500/month
- Accept Ozempic 2 mg off-label (if insurance covers it) and accept 7-8% weight loss instead of 15-17%
If you have obesity with prediabetes or metabolic syndrome:
This is the gray zone. You do not meet criteria for Ozempic's diabetes indication, but you have metabolic dysfunction that may progress to diabetes. Some providers prescribe Ozempic off-label and document prediabetes as the indication. Some prescribe Wegovy and fight the insurance denial. Some go directly to compounded semaglutide.
The clinical outcome depends on dose, not brand. If you can access 2.4 mg (via Wegovy, compounded semaglutide, or off-label Ozempic with creative dosing), you will see Wegovy-level weight loss. If you can only access 1-2 mg, you will see Ozempic-level weight loss.
If cost is the primary constraint:
Compounded semaglutide offers the best cost-to-outcome ratio. You can access any dose (including 2.4 mg) at $300-500/month, which is less than most Wegovy copays and far less than Wegovy cash price. The trade-off is that compounded semaglutide is not FDA-approved and requires self-injection from a vial rather than a pre-filled pen.
FormBlends specializes in connecting patients to compounded semaglutide and tirzepatide when brand-name options are unaffordable or inaccessible. Our providers prescribe the dose that matches your clinical goals, whether that is Ozempic-equivalent (1-2 mg) or Wegovy-equivalent (2.4 mg).
FAQ
Are Ozempic and Wegovy the same drug? Yes. Both contain semaglutide as the active ingredient. The difference is FDA-approved indication (diabetes vs weight loss) and maximum dose (2 mg for Ozempic, 2.4 mg for Wegovy). The molecular structure is identical.
Can I take Ozempic for weight loss if I don't have diabetes? Legally, yes. Your provider can prescribe Ozempic off-label for weight loss. The issue is insurance coverage (most plans will deny it for non-diabetic patients) and dose (Ozempic maxes out at 2 mg, which produces less weight loss than Wegovy's 2.4 mg).
Why does Wegovy cost more than Ozempic? Wegovy's list price is approximately 40% higher than Ozempic's because Novo Nordisk prices weight-loss medications higher than diabetes medications. Weight-loss drugs are often cash-pay (poor insurance coverage), so manufacturers price based on willingness-to-pay rather than formulary competition.
Will insurance cover Ozempic if I only want it for weight loss? Probably not. Most insurance plans require a diabetes diagnosis (elevated A1C or fasting glucose) to cover Ozempic. If you do not have diabetes, the claim will be denied. Some patients with prediabetes can get coverage if the provider documents metabolic dysfunction.
Can my doctor prescribe Wegovy if insurance won't cover it? Yes. Your doctor can write a prescription for Wegovy regardless of insurance coverage. You can fill it and pay cash ($1,400-1,600/month), appeal the insurance denial, or ask your provider about compounded semaglutide as a lower-cost alternative.
Is compounded semaglutide the same as Ozempic or Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved. It is prepared by a compounding pharmacy in response to an individual prescription. The dose can match Ozempic (1-2 mg) or Wegovy (2.4 mg), but the formulation and delivery method differ (vial and syringe vs pre-filled pen).
How much weight will I lose on Ozempic vs Wegovy? Clinical trial averages: Ozempic 1 mg produces 5% weight loss, Ozempic 2 mg produces 7-8% weight loss, Wegovy 2.4 mg produces 15-17% weight loss. Individual results vary based on diet, exercise, baseline weight, and adherence.
Can I switch from Ozempic to Wegovy? Yes. If you are on Ozempic 2 mg and want to escalate to Wegovy 2.4 mg, your provider can write a new prescription. You will need to go through the Wegovy titration schedule starting at 0.25 mg, or your provider may start you directly at 2.4 mg if you have already tolerated 2 mg on Ozempic.
Does Ozempic have the same side effects as Wegovy? Yes, but the frequency is dose-dependent. Wegovy 2.4 mg causes nausea in 44% of patients vs 28% at Ozempic 2 mg. The side effects (nausea, diarrhea, constipation, vomiting) are the same, but higher doses produce higher rates.
Why was Ozempic on shortage if it's a diabetes drug? Off-label prescribing for weight loss depleted Ozempic stock intended for diabetes patients. Providers prescribed Ozempic instead of Wegovy because insurance covered it. Demand exceeded Novo Nordisk's manufacturing capacity, and the FDA added Ozempic to the shortage list in March 2022.
Can I use Ozempic and Wegovy at the same time? No. Both are semaglutide. Using both would be double-dosing the same drug, which increases side effects and overdose risk without additional benefit. If you want a higher dose, ask your provider to prescribe a single higher-dose product.
What happens if I take Ozempic 2 mg but want the Wegovy 2.4 mg dose? Some providers prescribe two Ozempic injections per week to approximate 2.4 mg total weekly dose. This is off-label and not a standard regimen. The alternative is switching to Wegovy or compounded semaglutide at 2.4 mg.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
- Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
- Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018.
- Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
- Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.
- FDA Drug Shortage Database. Semaglutide injection. Updated March 2024.
- Novo Nordisk. Prescribing Information: Ozempic (semaglutide) injection. Updated 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →